Bracco Imaging SpA, Bracco Research Centre, Colleretto Giacosa, TO, Italy.
Charles River Saint Germain-Nuelles, Lyon, France.
J Magn Reson Imaging. 2021 Nov;54(5):1636-1644. doi: 10.1002/jmri.27693. Epub 2021 May 11.
Studies of gadolinium (Gd) clearance from animals in the first weeks after administration of gadolinium-based contrast agents (GBCAs) have previously looked at solitary timepoints only. However, this does not give information on differences between GBCAs and between organs in terms of Gd elimination kinetics.
To compare Gd levels in rat cerebellum, cerebrum, skin, and blood at 1, 2, 3, and 5 weeks after repeated administration of macrocyclic GBCAs.
Prospective.
One hundred eighty male Sprague-Dawley rats randomized to three groups (n = 60/group), received intravenous administrations of gadoteridol, gadoterate meglumine, or gadobutrol (0.6 mmol/kg for each) four times/week for 5 consecutive weeks. Rats were sacrificed after washout periods of 1, 2, 3, or 5 weeks.
FIELD STRENGTH/SEQUENCE: Not applicable.
Cerebellum, cerebrum, skin, and blood were harvested for Gd determination by inductively coupled plasma-mass spectrometry (15 animals/group/all timepoints).
Anova and Dunnett's test (data with homogeneous variances and normal distribution). Kruskal-Wallis and Wilcoxon's rank sum tests (data showing nonhomogeneous variances or a non-normal distribution, significance levels: P < 0.05, P < 0.01, and P < 0.001).
Gd levels in cerebellum, cerebrum, and skin were significantly lower after gadoteridol than after gadoterate and gadobutrol at all timepoints. Mean cerebellum Gd concentrations after gadoteridol, gadoterate, and gadobutrol decreased from 0.693, 0.878, and 1.011 nmol Gd/g at 1 week to 0.144, 0.282, and 0.297 nmol Gd/g at 5 weeks after injection. Similar findings were noted for cerebrum and skin. Conversely, significantly higher Gd levels were noted in blood after gadoteridol compared to gadobutrol at 1, 2, and 3 weeks and compared to gadoterate at all timepoints.
Gadoteridol is eliminated more rapidly from rat cerebellum, cerebrum, and skin compared to gadoterate and gadobutrol in the first 5 weeks after administration, resulting in lower levels of retained Gd in these tissues.
1 TECHNICAL EFFICACY: Stage 5.
先前研究表明，在给予基于钆的造影剂（GBCA）后的最初几周内，动物体内的钆清除情况仅在单一时间点进行了研究。然而，这并不能提供关于 GBCA 之间以及器官之间在 Gd 消除动力学方面的差异信息。
比较重复给予大环 GBCA 后 1、2、3 和 5 周时大鼠小脑、大脑、皮肤和血液中的 Gd 水平。
前瞻性。
180 只雄性 Sprague-Dawley 大鼠随机分为三组（每组 60 只），每周静脉注射 4 次，剂量分别为 0.6mmol/kg 的钆特醇、钆喷酸葡胺和钆布醇。在洗脱期 1、2、3 或 5 周后处死大鼠。
场强/序列：不适用。
通过电感耦合等离子体质谱法（每组 15 只动物/所有时间点）测定小脑、大脑、皮肤和血液中的 Gd 含量。
方差分析和 Dunnett 检验（具有同方差和正态分布的数据）。Kruskal-Wallis 和 Wilcoxon 秩和检验（具有非同方差或非正态分布的数据，显著性水平：P<0.05、P<0.01 和 P<0.001）。
在所有时间点，与钆特醇相比，大鼠小脑、大脑和皮肤中的 Gd 水平在给予钆喷酸葡胺和钆布醇后明显较低。在给予钆特醇、钆喷酸葡胺和钆布醇 1 周后，大鼠小脑 Gd 浓度分别为 0.693、0.878 和 1.011nmol Gd/g，5 周后分别降至 0.144、0.282 和 0.297nmol Gd/g。大脑和皮肤也有类似的发现。相反，与钆布醇相比，在 1、2 和 3 周时，钆特醇在血液中的 Gd 水平明显较高，与所有时间点的钆喷酸葡胺相比也较高。
与钆喷酸葡胺和钆布醇相比，在给予 GBCA 后的最初 5 周内，钆特醇从大鼠小脑、大脑和皮肤中的消除速度更快，导致这些组织中残留的 Gd 水平更低。
1 技术功效：5 级。
